Skip to main content
SpringerLink
Log in

Adjuvant Chemoendocrine Therapies In Pre- and Postmenopausal Breast Cancer (“Can you teach an old dog new tricks?”)

  • Conference paper
Endocrine Therapy of Breast Cancer V

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 29 Accesses

Abstract

Most breast cancer patients who remain disease free after local and regional treatment eventually relapse and die of or with overt metastases. This is true regardless of whether they received an appropriate local therapy. The current hypothesis ascribes the failure to obtain freedom from disease to occult micrometastatic disease already present at the time of diagnosis and first surgery [1]. This hypothesis has acquired indirect support from the results of clinical trials which showed no additional advantage in terms of disease-free or overall survival for a more radical local therapy [2,3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 1980 (302): 17–30, 78–90

    Article  PubMed  CAS  Google Scholar 

  2. Veronesi U, Cascinelli N, Greco M et al: Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985 (202): 702–707

    Article  PubMed  CAS  Google Scholar 

  3. Fisher B, Redmond C, Poisson R et al: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989 (320): 822–828

    Article  PubMed  CAS  Google Scholar 

  4. Cole MP: Prophylactic compared with therapeutic x-ray artificial menopause. 2nd Tenovus Workshop of Breast Cancer, 1970 pp 2–11

    Google Scholar 

  5. Berlin Nl: Research strategy in cancer: screening, diagnosis, prognosis. Hosp Practice 1975 (10): 83–91

    Google Scholar 

  6. Martin DS, Fugman RA: A role of chemotherapy as an adjunct to surgery. Cancer Res 1957 (17):1098–1101

    Google Scholar 

  7. Martin DS: Clinical implications of the interrelationship of tumor size and chemotherapeutic response. Ann Surg 1960 (151):97–100

    Article  PubMed  CAS  Google Scholar 

  8. Martin DS, Hayworth PE, Fugman RA: Enhanced cures of spontaneous murine mammary tumors with surgery, combination chemotherapy, and immunotherapy. Cancer Res 1970 (30): 709–716

    PubMed  CAS  Google Scholar 

  9. Karrer K, Humphreys SR: Continuous and limited courses of cyclophosphamide (NSC 26271) in mice with pulmonary metastases after surgery. Cancer Chemother Rep 1967 (51): 439–449

    Google Scholar 

  10. Mayo JG, Laster WR, Andrews CM, Schable FM: Success and failure in the treatment of solid tumors. III. Cure of metastatic Lewis lung carcinoma with methyl-CCNU (NSC 94551) and surgery-chemotherapy. Cancer Chemother Rep 1972 (56):183–195

    PubMed  CAS  Google Scholar 

  11. Martin DS, Fugman RA, Stolfi RL, et al: Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 1975 (59):89–109

    Google Scholar 

  12. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to spontaneous mutation rate. Cancer Treat Rep 1979 (63): 1727–1733

    PubMed  CAS  Google Scholar 

  13. Retsky MW, Wardwell RH, Swartzendruber DE, et al: Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data. Cancer Res 1987 (47): 4982–4997

    PubMed  CAS  Google Scholar 

  14. Cavalli F, Pedrazzini A, Martz G, Jungi WF, Brunner KW, Goldhirsch A, Mermillod B, Alberto P: Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Eur J Cancer Clin Oncol 1983 (19):1615–1624

    Article  PubMed  CAS  Google Scholar 

  15. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen: five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986 (4):459–471

    PubMed  CAS  Google Scholar 

  16. Osborne CK: Effects of estrogens and antiestrogens on cell proliferation. Implications for treatment of breast cancer. In: Osborne CK (ed) Endocrine Therapies in Breast and Prostatic Cancer. Kluwer Academic Publishers, Boston, 1988 pp111–129

    Chapter  Google Scholar 

  17. Kaufmann M, Jonat W, Caffier H, et al: Adjuvant systemic risk adapted cytotoxic +/E#x00a7 tamoxifen therapy in women with node-positive breast cancer. In: Salmon SE (ed) Adjuvant Therapy Of Cancer V. Grune & Stratton, Orlando, 1987 pp 337–346

    Google Scholar 

  18. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol 1990(8):1310–1320

    PubMed  CAS  Google Scholar 

  19. Falkson HC, Gray R, Wolberg WH, Falkson G: Adjuvant therapy of postmenopausal women with breast cancer- An ECOG phase III study. Proc ASCO 1989(8):19

    Google Scholar 

  20. Ludwig Breast Cancer Study Group: Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985 (3):1059–1067

    Google Scholar 

  21. Goldhirsch A, Gelber RD for the Ludwig Breast Cancer Study Group. Adjuvant treatment for early breast cancer: The Ludwig Breast Cancer Studies. NCI Monogr 1986(1): 55–70

    PubMed  Google Scholar 

  22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958 (53): 457–481

    Article  Google Scholar 

  23. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977(35): 1–39

    Article  PubMed  CAS  Google Scholar 

  24. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B (Methodology). 1972 (34): 187–220

    Google Scholar 

  25. Rivkin S, Green S, Metch B, et al: Adjuvant chemotherapy (CMFVP) vs oophorectomy followed by chemotherapy (OCMFVP) for premenopausal women with ER+ operable breast cancer with positive (+) axillary lymph nodes: An Intergroup study. Proc ASCO 1991 (10): 47

    Google Scholar 

  26. The International Breast Cancer Study Group: Late effects of adjuvant oophorectomy and chemotherapy upon pre-menopausal breast cancer patients. Ann Oncol 1990 (1):30–35

    Google Scholar 

  27. Nissen-Meyer R: Primary breast cancer: The effect of primary ovarian irradiation. Ann Oncol 1991 (2):343–346

    PubMed  CAS  Google Scholar 

  28. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast Cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988 (319): 1681–1692

    Google Scholar 

  29. Report on Medical Ethics. World Med Assoc Bull 1949 (1):109–111

    Google Scholar 

  30. Bonadonna G, Veronesi U, Brambilla C, et al: Primary’ chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. JNCI 1990 (82): 1537–1545

    Google Scholar 

  31. Hellman S, Hellman DS: Of mice but not men. Problems of the randomized clinical trial. N Engl J Med 1991 (324):1585–1589

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Ospedale San Giovanni, Bellinzona, Ospedale Civico, Lugano, and Ospedale Beata Vergine, Mendrisio, Switzerland

    Aron Goldhirsch

  2. Institut für medizinische Onkologie & International Breast Cancer Study Group Operation Office, Bern, Switzerland

    Monica Castiglione

  3. Harvard School of Public Health, and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Richard D. Gelber

Authors
  1. Aron Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Castiglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard D. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Ospedale Civico, via Tesserete 46, 6900, Lugano, Switzerland

    A. Goldhirsch

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Goldhirsch, A., Castiglione, M., Gelber, R.D. (1992). Adjuvant Chemoendocrine Therapies In Pre- and Postmenopausal Breast Cancer (“Can you teach an old dog new tricks?”). In: Goldhirsch, A. (eds) Endocrine Therapy of Breast Cancer V. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77662-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77662-5_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77664-9

  • Online ISBN: 978-3-642-77662-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation